immuneonco.com Open in urlscan Pro
154.85.61.91  Public Scan

Form analysis
1 forms found in the DOM

GET search.php

<form class="clearfix" action="search.php" method="get" onsubmit="if(this.search_keyword.value == ''){ alert('Search keyword cannot be empty!'); this.search_keyword.focus(); return false; }">
  <div class="serclose">X</div>
  <input type="search" name="search_keyword" class="txt" placeholder="Search...">
  <input type="submit" value="Search" class="btn">
</form>

Text Content

X

 * Company Company Overview Management Team Board of Directors
 * Science Technology Platforms Presentations Publications
 * PipeLine Pipeline Access to Investigational Drugs Policy
 * Collaboration Collaboration
 * Investors Investors
 * News Company news
 * Contact us Contact us
 * CN


 * Company
 * Science
 * PipeLine
 * Collaboration
 * Investors
 * News
 * Contact us
 * CN


X
Company overview




We are a science-driven biotechnology company dedicated to the development of
next-generation immuno-oncology therapies.




See details
Science & Technology
We have established an integrated in-house R&D platform that covers target
selection and validation, drug discovery, high-throughput screening, molecule
design, preclinical studies, CMC and IND-enabling capabilities.
See details
Science & Technology
Integrated proprietary R&D engine anchored around our deep understanding of
tumor immunology, continuously driving the discovery and development of
innovative next-generation immunotherapies.
See details
Science & Technology
We have established an integrated in-house R&D platform that covers target
selection and validation, drug discovery, high-throughput screening, molecule
design, preclinical studies, CMC and IND-enabling capabilities.
See details
Science & Technology
Integrated proprietary R&D engine anchored around our deep understanding of
tumor immunology, continuously driving the discovery and development of
innovative next-generation immunotherapies.
See details

News Center

 * 08-31
   2022
   
   ImmuneOnco Published crystal protein structure of IMM01
   On August 31, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
   (hereinafter referred to as "ImmuneOnco" and the com......
   See details
 * 08-29
   2022
   
   IMM40H was approved almost simultaneously by China NMPA and US FDA for
   clinical trial research
   On August 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
   (hereinafter referred to as "ImmuneOnco" and the com......
   See details
 * 08-06
   2022
   
   ImmuneOnco won "Drug Innovation Award" by Securities Times
   On August 6, 2022, the Securities Times Biomedical Innovation Forum and the
   2nd Drug Innovation Award Ceremony hosted ......
   See details

Company Company Overview Management Team Board of Directors Science Technology
Platforms Presentations Publications Pipeline Pipeline Access to Investigational
Drugs Policy Collaboration Collaboration Inverstors&Publications Investors News
Company news Contact us Contact us
Copyright © 2020 ImmuneOnco All Rights Reserved Shanghai ICP Bei No.15048165